Cefotetan (Cefotetan Disodium) Patent Expiration, LOE Window & CMS Spending

Cefotetan (Cefotetan Disodium) by Fresenius Kabi: Multi-Source Generic Molecule, 0 AB generics, $58K 2024 CMS Part D & Medicaid spend, and 2 CA HCAI SB 17 wholesale price filings.

Regulatory & Reimbursement Dimension Verified Value
Consolidated SponsorFresenius Kabi
FDA Application & PathwayReconciled (ANDA)
Exclusivity / Cliff HorizonMulti-Source Generic Molecule
Core Active-Ingredient LOE DateNot listed / N/A
Last Listed Patent or Exclusivity DateNot listed / N/A
Orange Book Patents (*PED Extensions)0 patents (0 *PED)
Active AB-Rated Generic Competitors0
2024 CMS Total Public Spend$58K
2024 Medicare Part D Spend$0
2024 Medicaid Spend$58K
Reported Wholesale Price Change (CA SB 17)2 WAC filings (max 25.9% 2-yr change)

Related Filings Across Meru Platforms

Verified cross-ledger federal filings for Fresenius / Fresenius Kabi across sibling Meru public-data platforms.